Mitral Regurgitation Chronic: Difference between revisions
Varun Kumar (talk | contribs) No edit summary |
m (MR: Chronic MR moved to Mitral Regurgitation Chronic) |
(No difference)
| |
Revision as of 01:37, 27 February 2011
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [3] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch. Individuals with chronic mitral regurgitation can be treated with vasodilators as well. In the chronic state, the most commonly used agents are ACE inhibitors and hydralazine. Studies have shown that the use of ACE inhibitors and hydralazine can delay surgical treatment of mitral regurgitation1,2. The current guidelines for treatment of mitral regurgitation limit the use of vasodilators to individuals with hypertension
There are two surgical options for the treatment of mitral regurgitation: mitral valve replacement and mitral valve repair.
Indication for Surgery
ACC/AHA guidelines for management
References
1. Greenberg BH, Massie BM, Brundage BH, Botvinick EH, Parmley WW, Chatterjee K. Beneficial effects of hydralazine in severe mitral regurgitation. Circulation. 1978 Aug;58(2):273-9. (Medline abstract)
2. Hoit BD. Medical treatment of valvular heart disease. Curr Opin Cardiol. 1991 Apr;6(2):207-11. (Medline abstract)